Pivotal adjuvant trials such as HERA and BCIRG-006 in patients with HER2-overexpressing breast cancer paved the way for numerous studies with HER2-targeted drugs in different cancer patient populations [19]. The gene discussed is ERBB2; the disease is cancer.